Home » Amgen Trial Finds No Heart Benefit With Aranesp
Amgen Trial Finds No Heart Benefit With Aranesp
A trial of Amgen Inc’s Aranesp found the blockbuster anemia drug does not have a significant effect on the risk of heart attack and other cardiac events in kidney patients, the company said.
Forbes
Forbes
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May